N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial.

J Neuroinflammation · 2023 · PMC10498575 · PMID 37705084

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Oral GlcNAc therapy reduced serum levels of IFNγ, IL-6 and IL-17 in the 12 g but not the 6 g cohort, although a positive trend was observed at the 6 g cohort for IFNγ (Fig. 3 A–L).

also in 11,005 other papers

showed a trendno p-value reported

This showed a trend to reduced EDSS after 4 weeks of GlcNAc in both the 6 g and 12 g cohorts (Additional file 1 : Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.